Evogene Ltd (EVGN)

[MWM]

$EVGN starting to go, a breakout will be big...

[Porterhouse10]

Movin' on Up!

[Fress]

Genome Stocks the next FANG stocks according to Cathie Wood of ARKG.


EVGN Quiet name getting ready to go surge to all time new highs of $6.00 will go parabolic soon!


Cathie Wood from ARKG ETF is investing in companies that she sees has exponential growth & scaling EVGN is one of those companies in her ARKG ETF where she highlights Gene editing & AI will be future underpinnings of successful companies EVGN is built around next level bleeding cutting edge Gene editing and AI technology.

Cathie Wood on Gene editing stocks in her ETF & recent success stories.

Shares are scarce only 35 million 45%+ owned by Insiders & institutions

most of the shares are accounted for and are being held by savvy investors. double digit dollars coming sooner than later.


https://ksusentinel.com/2021/01/11/global-agricultural-biotechnology-market-outlook-2020business-overview-by-2027-available-in-latest-reportbiomica-evogene-ltd-canonic-ltd-bayer-ag-valent-biosciences-llc/

one of my top picks for 2021


Evogene’s CPB based solutions utilize comprehensive and integrated computational biology to provide life-science companies with tailor-made solutions for product discovery and development.
Microbes, small molecules and genetic genome elements can be applied to a wide variety of products within human health, agriculture and industrial applications.



EVGN WEBSITE:
https://www.evogene.com/



Gene editing AI platform applications for Biotech and agriculture.


Subsidiaries
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf

Biomica:
2021 Proof of concept, first-in-man study – Immuno-oncology program.


EVGN green gene editing product coming next year can be a blockbuster rivaling Monsantos Roundup which had billions yearly in sales from 2015.

What is an engineered green weed killer product worth in the market these days. coming to market in 2022

REHOVOT, Israel, Jan. 5, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, provided today a year-end update for the CRISPR-IL consortium, of which it is a member and Evogene's CSO, Dr. Eyal Emmanuel, serves as the consortium's Chairman. The CRISPR-IL consortium, which is supported by the Israeli Innovation Authority, was established to develop an artificial intelligence-based system, for CRISPR-CAS based workflows, "Go-Genome", providing end-to-end genome-editing, with improved precision and efficiency.
https://www.biospace.com/article/releases/evogene-provides-2020-year-end-update-for-crispr-il-consortium/

Kathy Woods of ARKG ETF has been buying EVGN
Kathy woods from ARKG all star stock picker best in class.

https://ark-funds.com/arkg

EVGN Biz Presentation
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf

EVGN Subsidiary's which they own close to 100% in all
https://www.evogene.com/subsidiaries/
(1) Biomica Human Microbiome (gene editing)

Biomica Mission: Discovery and development of novel therapies for microbiome-related human disorders using computational predictive biology.

(2).Canonic
Medical Cannabis

Canonic Mission: Commercialization of precise & stable medical cannabis products for better therapeutic effects.

(3)
AgPlenus
Ag-Chemicals

AgPlenus Mission: Design next generation effective, sustainable and safer crop protection products by leveraging predictive biology.

(4) Lavie Bio
Ag Biologicals

Lavie Bio Mission: Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products.


(5)Castera
Castor Oil Production

Castera Mission: Provide farmers with the most advanced Castor seeds & Ag-service solutions
--------------------------------------------------------------------

2022 commercial product of a (Green) weed killer that will take market share from Monsanto round up massive revenue potential next year!


Oncology pipeline to kill tumors..


EVGN is a wealth creator buy what you can afford and lock up your shares GTC sky high.


Genome Stocks-Gene Editing.
$BEAM 5.4 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders


Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
https://tenor.com/view/oh-yeah-dance-dancing-dances-party-gif-17442404


$EVGN

[Porterhouse10]

Crunchy crunch!

[MWM]

https://www.linkedin.com/posts/evogene_agplenus-novel-mode-of-action-herbicide-activity-6744591094660657152-4qKy

[Porterhouse10]

Little sideways action, consolidating a bit, 1 month chart is stout, ready for that green arrow headed North.

[Fress]

Boomage.

this is one of my favorite plays of 2021 add all you can before the stock launches into a new orbit of trading. $6.01 will be a blue sky breakout and a new all time high and then we go into the higher realms.

EVGN shares are very scarce insiders and institutions own almost 50% including Cathie Wood of ARKG ETF EVGN has 35 million shares total. Not that many shares left being gobbled up by smart money. Could see a BNGO move coming this way sooner than later.


EVGN double digit dollars coming.


I see the angles before they are being played.


always early.



EVGN wants to go parabolic seen so many stocks recently that didn't deserve a massive move up. EVGN does and will you can make book on that.


https://gifer.com/en/FTW



Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 190 million market cap 35 million shares 45% owned by institutions & insiders


$EVGN

[Fress]

Added heavy at the open.



Cathie Wood of ARKG ETF owns EVGN & so do I. I'm buying more at the open before it breaks its all time high of $6.00 (blue sky breakout)


EVGN Biz Presentation
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf

Evogene website:
https://www.evogene.com/


Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders



$EVGN

[Porterhouse10]

Nets are cast if she wants to dip, Giddy Up!

[Porterhouse10]

Prime Time!

[Fress]

great Long term hold. gene editing is the future and its market cap is so small. Easy 30 bagger from here in 5 years.


Tons of potential for a parabolic run.



we should see double digits soon. Billion dollar plus market cap by the end of 2021



Cathie Wood of ARKG ETF owns EVGN & so do I. I'm buying more at the open before it breaks its all time high of $6.00 (blue sky breakout)


EVGN Biz Presentation
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf

Evogene website:
https://www.evogene.com/


Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders


$EVGN

[MWM]

$EVGN this is fun too...

Corteva Investment in Lavie Bio in August 2019 includes Board Appointment
In August 2019, Evogene announced that Corteva was making a substantial investment in Lavie Bio and was appointing a representative on Lavie Bio's board of directors.

The announcement was very significant as Corteva is a leading multinational seed and crop protection company with a $21 billion market cap, spun out of DowDupont last June 2019.

Corteva's investment in Lavie Bio was valued at approximately $27.5 million, including the exchange of all shares of Corteva’s wholly-owned subsidiary Taxon Biosciences along with a US$10 million equity investment by Corteva in consideration of approximately 30% of Lavie Bio’s equity (which ultimately worked out to be approximately 28% of Lavie Bio's equity according to Evogene's Form 20F filed July 27, 2020 with the SEC).

I have assumed that the shares in Taxon Bioscience were valued by the parties at approximately $17.5 million because of the reference in Evogene's Consolidated Statement of Cash Flows for Q3 2019 (3-month period ending September 30, 2019) where the sum of $17,449,000 was attributed to the "Acquisition of intangible assets from non-controlling interests against the issuance of subsidiary's ordinary shares." There are no other acquisitions of intangible assets by any of Evogene's subsidiaries in Q3 2019 in which shares of the subsidiary were issued other than Lavie Bio's acquisition of the shares of Taxon Bioscience from Corteva as announced in August 2019.

The assets of Taxon Biosciences include an IP portfolio, a large microbial collection, and product candidate pipeline, which are now integrated into Lavie Bio’s pipeline, and contributed to Lavie Bio's technological capabilities.

According to Lavie Bio's CEO, after the Taxon Bioscience acquisition from Corteva, it now has a combined collection of 140,000 strains from 4 different continents, which is now one of the largest such databases in the world.

In addition (as set out in Form 20F, filed July 27, 2020), Corteva’s August 2019 investment in Lavie Bio provided Corteva with certain future rights to obtain commercial licenses to Lavie Bio’s candidate products, mainly in corn and soy.

Corteva's 28% equity investment in Lavie Bio was actually an evolutionary step in the Corteva/Evogene relationship which began in July 2017, when Evogene entered into a multiyear collaboration with DuPont Pioneer (now Corteva) for the research and development of novel microbial biostimulant seed treatments for the improvement of corn productivity globally. Under the earlier 2017 multi-year collaboration agreement, Lavie Bio is still entitled to milestone payments for the advancement of candidate strains, and royalties from product sales. The precise financial details of this collaboration deal with Corteva are not disclosed.

Corteva has now appointed its representative, Rowdy Smith, Global Portfolio Leader for the Seed Applied & Biological Technologies for Corteva Agriscience, to Lavie Bio's board of directors.

Assuming that the Corteva investment in Lavie Bio last August 2019 is valued at $27.5 million for Corteva's 28% interest in Lavie Bio, that calculates into a post-transaction valuation of Lavie Bio of approximately $100,000,000 as of August 2019 (which would value Evogene's 72% interest in Lavie Bio at approximately $72 million).

Since then, Lavie Bio has made further progress and arguably is now more valuable.

https://seekingalpha.com/article/4370400-evogene-hidden-gems-of-computational-predictive-biology-part-2-of-4-lavie-bio

[MWM]

$EVGN I like this DD...

Assuming Lavie Bio (or its partners or agents) can obtain a 20% market share of the first focus market's 25 million acres, that works out to be $30 million (5 million acres at $6.00 per acre) for just the test market of "spring wheat". The cost of production of LAV211 is relatively low with an estimated gross margin in excess of 80%.

"Winter Wheat" is another potential market for LAV211. Winter wheat is planted in or about November, before the winter snow. After the snow melts, the winter wheat plants grow and are harvested in early spring. While the initial indication for LAV211 is "spring wheat," LAV211 may be expanded into the winter wheat at the same time in the future. According to Lavie Bio's CEO, the LAV211 market for winter wheat is potentially 5 to 10 times larger than spring wheat. The development testing and timing of LAV211 for "winter wheat" has not yet been released.

LAV211 can also likely be expanded into other agricultural crops such as oats, which is a lucrative market now because of the oatmilk market.

Potentially, LAV211 could generate annual revenues in the $100 million range for "spring wheat" and other products with commercial sales in the spring wheat market beginning in 2022. The market for LAV211 could be expanded further to other products but no further details have yet been provided. I note that Lavie Bio's Product Pipeline slide (shown earlier in this article) indicates a potential expansion to 500 million acres (compared to the 25 million acre "spring wheat" market.

https://seekingalpha.com/article/4370400-evogene-hidden-gems-of-computational-predictive-biology-part-2-of-4-lavie-bio

[MWM]

$EVGN Artificial intelligence-driven platform for genome editing presented

Evogene Ltd. a computational biology company working on life-science product development across several market segments, provided today a year-end update for the CRISPR-IL consortium, of which it is a member. The CRISPR-IL consortium, which is supported by the Israeli Innovation Authority, was established to develop an artificial intelligence-based system, for CRISPR-CAS based workflows, “Go-Genome“, providing end-to-end genome-editing, with improved precision and efficiency.

Today, the company announces the CRISPR-IL’s completion of a first version of the artificial intelligence-driven platform for genome-editing, design; a major milestone in the development roadmap of “Go-Genome“. Also announced is the addition of two new members, Better Seeds and FreeZem, active in the areas of agriculture and alternative protein sourced from insects, respectively. The addition of these two companies is expected to widen the system’s applicability.

CRISPR-CAS is a genome-editing technology that enables precise genomic changes, which are expected to lead to the development of a new set of products and services. The products and services are expected to include human therapeutics such as CAR-T treatments and curing monogenic diseases, and agricultural uses such as adding nutritional value to food products.

Read the complete article here.
https://www.hortidaily.com/article/9281561/artificial-intelligence-driven-platform-for-genome-editing-presented/

Publication date: Wed 6 Jan 2021

[Fress]

copy that MWM! this stock has tremendous upside return on investment.

Biomica Mission: Discovery and development of novel therapies for microbiome next generation therapeutics-related human disorders using computational predictive biology. Gene editing-AI platform.

http://www.evogene.com



https://www.biomicamed.com/



adding to my stash in the am before this launches.



Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 750 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders




$EVGN

[MWM]

Goldmine here. Amazed it trades on the cheap!

[Fress]

Some people are going to become multi millionaires investing in this stock at these levels.

https://www.evogene.com/solutions/#generator


https://www.evogene.com/solutions/#chempass


https://www.evogene.com/solutions/#microboost


When biology meets disruptive technologies
Based on two decades of targeted research, at an investment of tens of millions of dollars, and in collaboration with industry leaders, the CPB (Computational Predictive Biology) platform promotes and optimizes life-science product discovery and development. Integration of deep scientific understandings with big data and artificial intelligence (AI), substantially increases the probability of successful life-science product development, while reducing time and cost.


Gene editing AI platform applications for Biotech and agriculture.


Subsidiaries
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf

Biomica:
2021 Proof of concept, first-in-man study – Immuno-oncology program.


EVGN green gene editing product coming next year can be a blockbuster rivaling Monsantos Roundup which had billions yearly in sales from 2015.

What is an engineered green weed killer product worth in the market these days. coming to market in 2022



https://www.evogene.com/partnerships/


CRISPR-CAS is a revolutionizing genome-editing technology that enables precise genomic changes, which are expected to lead to the development of a new set of products and services. The products and services are expected to include human therapeutics such as CAR-T treatments and curing monogenic diseases, and agricultural uses such as adding nutritional value to food products, among others. This technology can result in products and services in a wide range of markets that could potentially reach a total market size of $500 billion in 2025.


Evogene led the consortium's work package for the development of this first version of a genome-editing design platform. The platform is intended to enable predicting the design of guide-RNA, which directs the CRISPR-CAS to make on-target DNA modifications. Moreover, the developed platform has already produced guide-RNA predictions, which are currently being utilized by the consortium members to perform genome-editing experiments in pharma and agriculture.

These new capabilities are expected to extend the range of Evogene's GeneRator AI solution by supporting products based on changes in genetic elements via genome editing.

https://www.prnewswire.com/il/news-releases/evogene-provides-2020-year-end-update-for-crispr-il-consortium-301200881.html


EVGN Biz Presentation
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf

Evogene website:
https://www.evogene.com/


Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders

$EVGN

[Fress]

Buy all you can under $5.50


absolute monster in the making.


always early!


$6.01 is a new all time high blue sky breakout for this stock next sky is the limit for a quality small cap gene editing company.



Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders



$EVGN

[MWM]

https://www.evogene.com/subsidiaries/

[MWM]

I'm really fascinated by this company and all the subsidiaries.

Gene Editing for Agriculture sounds like it has MASSIVE potential...

https://www.prnewswire.com/news-releases/lavie-bio-provides-product-pipeline-update-for-2020-301198936.html

[midastouch017]

5.22+0.48 (+10.02%)
As of 2:46PM EST.

Volume 1,435,214
Avg. Volume 1,345,130

Nice, very nice!

[Porterhouse10]

Liking it, 1 month chart has some power!

[Fress]

Quiet name getting ready to explode. Should go parabolic soon!



$20.00 target in 2021 could come by Q2 or even Q1


Cathie Wood from ARKG loves EVGN.


This is one of my top picks for 2021 and beyond.


35 million shares almost half owned by institutions and insiders.


shares are scarce and are going to be fetching premiums from here on out. This can double or triple in a blink of an eye..


lots of catalysts here exposure to biotech cannabis and agriculture.


CRISPR-CAS is a revolutionizing genome-editing technology that enables precise genomic changes, which are expected to lead to the development of a new set of products and services. The products and services are expected to include human therapeutics such as CAR-T treatments and curing monogenic diseases, and agricultural uses such as adding nutritional value to food products, among others. This technology can result in products and services in a wide range of markets that could potentially reach a total market size of $500 billion in 2025.


Evogene led the consortium's work package for the development of this first version of a genome-editing design platform. The platform is intended to enable predicting the design of guide-RNA, which directs the CRISPR-CAS to make on-target DNA modifications. Moreover, the developed platform has already produced guide-RNA predictions, which are currently being utilized by the consortium members to perform genome-editing experiments in pharma and agriculture.

These new capabilities are expected to extend the range of Evogene's GeneRator AI solution by supporting products based on changes in genetic elements via genome editing.



EVGN WEBSITE:
https://www.evogene.com/

EVGN Biz Presentation
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf

EVGN Subsidiary's which they own close to 100% in their companies.
https://www.evogene.com/subsidiaries/
(1) Biomica Human Microbiome (gene editing)

Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders


$EVGN

[MWM]

$EVGN I think the Breakout is upon us. $ARKG is just too hot. I added a lot of shares the last two days, $5 will be history soon...

[MWM]

#50

[Porterhouse10]

Been in ARK INVEST ARKG since $46, or avg is $46, 2021-2022 gonna be huge, for this one and beyond jmo, but lovin it

[Fress]

CRISPR-CAS is a revolutionizing genome-editing technology that enables precise genomic changes, which are expected to lead to the development of a new set of products and services. The products and services are expected to include human therapeutics such as CAR-T treatments and curing monogenic diseases, and agricultural uses such as adding nutritional value to food products, among others. This technology can result in products and services in a wide range of markets that could potentially reach a total market size of $500 billion in 2025.


Evogene led the consortium's work package for the development of this first version of a genome-editing design platform. The platform is intended to enable predicting the design of guide-RNA, which directs the CRISPR-CAS to make on-target DNA modifications. Moreover, the developed platform has already produced guide-RNA predictions, which are currently being utilized by the consortium members to perform genome-editing experiments in pharma and agriculture.

These new capabilities are expected to extend the range of Evogene's GeneRator AI solution by supporting products based on changes in genetic elements via genome editing.


$EVGN

[Fress]

These market makers are trying hard to accumulating EVGN shares before the stock launches to double digit dollars very obvious. A monster move can happen at anytime! timing is everything in the market!!

A little volume and this will launch into a new orbit of $6.00+ an all time high for the stock this is a beautiful blue sky break out in the making. I have hit an array of 10x stock pics last year EVGN will treat my portfolio well.

know what you own and hit the ask with authority. next lock and key the shares in the vault they are golden.


EVGN shares are very scarce. Add now before it surges to new highs and beyond.


$EVGN

[MWM]

$EVGN joined you here

[Fress]

Cathie Wood founder of ARKG only invests in companies that will exponentially grow for instance Tesla early BTC early BEAM & EDIT early and now EVGN with a cutting edge gene editing platform for a variety of applications including biotech, Cannabis, Agriculture.
She believes Genome stocks will become the next generation FANG stocks to lead the markets.


https://www.evogene.com/subsidiaries/


https://www.evogene.com/

EVGN Biz Presentation
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf


Evogene Ltd. (NASDAQ): EVGN is a leading gene editing computational biology company targeting to revolutionize life-science product development.

Evogene Provides 2020 Year-End Update for CRISPR-IL Consortium
Progress includes completion of a first version of the artificial intelligence-driven platform for genome-editing.
https://www.prnewswire.com/il/news-releases/evogene-provides-2020-year-end-update-for-crispr-il-consortium-301200881.html


Genome Stocks-Gene Editing.
$BEAM 5 billion market cap ARKG ETF
$EDIT 5.1 billion market cap ARKG ETF
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 750 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders ARKG ETF



$EVGN

[Porterhouse10]

Thx again, nice details

[Fress]

I think it is going to go parabolic sooner than later. This is a long term hold for double digit dollars.


BNGO has a 4x market cap the market capitalization of EVGN completely insane. I know EVGN is a company with superior technology, team, share structure nearing 50% owned by insiders & institutions including ARKG ETF compared to BNGO.


small cap cutting edge technology gene editing companies is the keen place to be invested for the coming years.


EVGN 35 million shares almost half accounted for by insiders & institutions. Plus lots of savvy biotech investors in gene editing are holding EVGN stock are in strong hands and their accumulating shares. Probably only a few million shares still floating around.


EVGN Buy & hold and put GTC orders in at sky high prices.


EVGN Blue sky break out to all time highs of $6.00 are coming next the sky is the limit.


$BNGO 770 million market cap
$EVGN 175 million market cap

[Porterhouse10]

Tiny Float!

[Fress]

Thanks! EVGN small cap and gene editing is where the smart money is invested for 2021

EVGN very limited float here. 45% of the 35 million shares owned by Insiders & Institutions.


company has lots of catalysts and hammers are about to drop talked to a member of EVGN investor relations on Monday.


Genome Stocks are the next FANG stocks according to Cathie Wood of ARKG. This stock is a $1.00 from its ALL TIME HIGH.

one of my top picks for 2021

Evogene’s CPB based solutions utilize comprehensive and integrated computational biology to provide life-science companies with tailor-made solutions for gene-editing product discovery and development.
Microbes, small molecules and genetic genome elements can be applied to a wide variety of products within human health, agriculture and industrial applications.



EVGN WEBSITE:
https://www.evogene.com/


REHOVOT, Israel, Jan. 5, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, provided today a year-end update for the CRISPR-IL consortium, of which it is a member and Evogene's CSO, Dr. Eyal Emmanuel, serves as the consortium's Chairman. The CRISPR-IL consortium, which is supported by the Israeli Innovation Authority, was established to develop an artificial intelligence-based system, for CRISPR-CAS based workflows, "Go-Genome", providing end-to-end genome-editing, with improved precision and efficiency.
https://www.biospace.com/article/releases/evogene-provides-2020-year-end-update-for-crispr-il-consortium/

Cathie Wood of ARKG ETF has been buying EVGN
Cathie wood from ARKG all star stock picker best in class.

https://ark-funds.com/arkg

EVGN Biz Presentation
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf

EVGN Subsidiary's which they own close to 100% in all their companies.
https://www.evogene.com/subsidiaries/
(1) Biomica Human Microbiome (gene editing)

Biomica Mission: Discovery and development of novel therapies for microbiome-related human disorders using computational predictive biology.

(2).Canonic
Medical Cannabis

Canonic Mission: Commercialization of precise & stable medical cannabis products for better therapeutic effects.

(3)
AgPlenus
Ag-Chemicals

AgPlenus Mission: Design next generation effective, sustainable and safer crop protection products by leveraging predictive biology.

(4) Lavie Bio
Ag Biologicals

Lavie Bio Mission: Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products.


(5)Castera
Castor Oil Production

Castera Mission: Provide farmers with the most advanced Castor seeds & Ag-service solutions
--------------------------------------------------------------------

2022 commercial product of a (Green) weed killer that will take market share from Monsanto round up which has BILLION is sales every year.


EVGN cutting edge gene editing AI Oncology pipeline to kill tumors.




https://www.tradingview.com/symbols/NASDAQ-EVGN/technicals/

Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders


$EVGN

[Foxxycleopatra]

In case you’re interested, her name is Cathie Wood

[Fress]

Last trade 4.87 shorts are going to get their clocks cleaned. Shorting a Kathy Woods gene editing ARKG ETF stock has to be the stupidest thing one can do. If you sold today you got robbed for your shares.

ARKG ETF Holdings:
https://ark-funds.com/wp-content/fundsiteliterature/holdings/ARK_GENOMIC_REVOLUTION_MULTISECTOR_ETF_ARKG_HOLDINGS.pdf


know what you own.

EVGN website:
https://www.evogene.com/


EVGN Biz Presentation:
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf

REHOVOT, Israel, Jan. 5, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, provided today a year-end update for the CRISPR-IL consortium, of which it is a member and Evogene's CSO, Dr. Eyal Emmanuel, serves as the consortium's Chairman. The CRISPR-IL consortium, which is supported by the Israeli Innovation Authority, was established to develop an artificial intelligence-based system, for CRISPR-CAS based workflows, "Go-Genome", providing end-to-end genome-editing, with improved precision and efficiency.
https://www.biospace.com/article/releases/evogene-provides-2020-year-end-update-for-crispr-il-consortium/



Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders


$EVGN

[Porterhouse10]

Hold the line!

[Porterhouse10]

Looking good, love the space, thx as well for your input on the Board

[Fress]

People this has potential for a parabolic move its a dollar away from its all time high $6.00 then a clear sky breakout....

Thanks Midas People who buy at these levels are going to look back and wish they loaded more.

A product that is a year out that will be green friendly weed killer that will take market share from Monsanto roundup.

I have done very well following Kathy woods investments in the genome space she is one of the smartest investors in the world. This stock is going to outperform gene-editing is the space to be invested in.


What it means
How much money does Monsanto make from Roundup? In 2015, the company made nearly $4.76 billion in sales and $1.9 billion in gross profits from herbicide products, mostly Roundup. That represents a significant portion of the global glyphosate market, although the company will continue to lose market share to generic competitors as demand grows. Therefore, as far as Monsanto is concerned, the road to the future will be paved with seeds and genomics products, not chemical herbicides


Very excited to be an investor and watch this company transform into a genome editing blue chip stock with a multi billion market valuation in the future.


They have some many angles love the oncology and Ag & Cannabis angles very diversified pipeline and a great management team including ARKG Kathy woods as a institutional investor.

lots of catalysts coming in first half of 2021 & beyond!



The Company announces today, CRISPR-IL's completion of a first version of the artificial intelligence-driven platform for genome-editing, CRISPR-CAS based, design; a major milestone in the development roadmap of "Go-Genome". Also announced is the addition of two new members, Better Seeds and FreeZem, active in the areas of agriculture and alternative protein sourced from insects, respectively. The addition of these two companies is expected to widen the system's applicability.


EVGN website:
https://www.evogene.com/



EVGN subsidiaries:
https://www.evogene.com/subsidiaries/

EVGN Presentation
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf

Biomica's Mission
Discovery and development of novel therapies
for microbiome-related human disorders using
computational biology.


Product Pipeline
Immuno-oncology
BMC121 Combination therapy for cancer
with checkpoint inhibitors
BMC127 Combination therapy for cancer
with checkpoint inhibitors
GI related disorders
BMC321 | Inflammatory Bowel Disorder (IBD)
BMC322 | Inflammatory Bowel Disorder (IBD)
BMC426 | Irritable Bowel Syndrome (IBS)
MDRO
(Multi Drug resistant organisms)
BMC201 | Clostridioides difficile infection (CDI)


Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders




$EVGN

[midastouch017]

Thanks. Just made it a sticky

[midastouch017]

You did well, i forsee a p/t of
$10-12 in a year from now, easy.
Many irons in the fire with this
company. I like the various ops.

[Porterhouse10]

Nice DD, Thanks, and a follow!

[Fress]

Genome Stocks are the next FANG stocks according to Kathy Woods of ARKG. This stock is a $1.00 from its ALL TIME HIGH.

one of my top picks for 2021

Evogene’s CPB based solutions utilize comprehensive and integrated computational biology to provide life-science companies with tailor-made solutions for product discovery and development.
Microbes, small molecules and genetic genome elements can be applied to a wide variety of products within human health, agriculture and industrial applications.



EVGN WEBSITE:
https://www.evogene.com/


REHOVOT, Israel, Jan. 5, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, provided today a year-end update for the CRISPR-IL consortium, of which it is a member and Evogene's CSO, Dr. Eyal Emmanuel, serves as the consortium's Chairman. The CRISPR-IL consortium, which is supported by the Israeli Innovation Authority, was established to develop an artificial intelligence-based system, for CRISPR-CAS based workflows, "Go-Genome", providing end-to-end genome-editing, with improved precision and efficiency.
https://www.biospace.com/article/releases/evogene-provides-2020-year-end-update-for-crispr-il-consortium/

Kathy Woods of ARKG ETF has been buying EVGN
Kathy woods from ARKG all star stock picker best in class.

https://ark-funds.com/arkg

EVGN Biz Presentation
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf

EVGN Subsidiary's which they own close to 100% in all
https://www.evogene.com/subsidiaries/
(1) Biomica Human Microbiome (gene editing)

Biomica Mission: Discovery and development of novel therapies for microbiome-related human disorders using computational predictive biology.

(2).Canonic
Medical Cannabis

Canonic Mission: Commercialization of precise & stable medical cannabis products for better therapeutic effects.

(3)
AgPlenus
Ag-Chemicals

AgPlenus Mission: Design next generation effective, sustainable and safer crop protection products by leveraging predictive biology.

(4) Lavie Bio
Ag Biologicals

Lavie Bio Mission: Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products.


(5)Castera
Castor Oil Production

Castera Mission: Provide farmers with the most advanced Castor seeds & Ag-service solutions
--------------------------------------------------------------------

2022 commercial product of a (Green) weed killer that will take market share from Monsanto round up


Oncology pipeline to kill tumors




https://www.tradingview.com/symbols/NASDAQ-EVGN/technicals/

Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders

[Porterhouse10]

Just bought 680 shares from 4.81-4.96 $ EVGN

[midastouch017]

Evogene Provides 2020 Year-End Update for CRISPR-IL Consortium

https://finance.yahoo.com/news/evogene-provides-2020-end-crispr-120000314.html

Tue, January 5, 2021, 2:00 PM GMT+2

Progress includes completion of a first version of the artificial intelligence-driven platform for genome-editing

REHOVOT, Israel, Jan. 5, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, provided today a year-end update for the CRISPR-IL consortium, of which it is a member and Evogene's CSO, Dr. Eyal Emmanuel, serves as the consortium's Chairman. The CRISPR-IL consortium, which is supported by the Israeli Innovation Authority, was established to develop an artificial intelligence-based system, for CRISPR-CAS based workflows, "Go-Genome", providing end-to-end genome-editing, with improved precision and efficiency.

The Company announces today, CRISPR-IL's completion of a first version of the artificial intelligence-driven platform for genome-editing, CRISPR-CAS based, design; a major milestone in the development roadmap of "Go-Genome". Also announced is the addition of two new members, Better Seeds and FreeZem, active in the areas of agriculture and alternative protein sourced from insects, respectively. The addition of these two companies is expected to widen the system's applicability.

CRISPR-CAS is a revolutionizing genome-editing technology that enables precise genomic changes, which are expected to lead to the development of a new set of products and services. The products and services are expected to include human therapeutics such as CAR-T treatments and curing monogenic diseases, and agricultural uses such as adding nutritional value to food products, among others. This technology can result in products and services in a wide range of markets that could potentially reach a total market size of $500 billion in 2025.[1]

While current CRISPR-CAS based workflows target precise areas within the DNA, these workflows still face several challenges, which prevent more extensive use of this technology, including (i) accidental off-target modification, (ii) inefficient modifications requiring repeated trials, and (iii) inaccurate measuring tools to ascertain that the modification was effective as intended. The CRISPR-IL consortium was established to address these challenges.

Evogene led the consortium's work package for the development of this first version of a genome-editing design platform. The platform is intended to enable predicting the design of guide-RNA, which directs the CRISPR-CAS to make on-target DNA modifications. Moreover, the developed platform has already produced guide-RNA predictions, which are currently being utilized by the consortium members to perform genome-editing experiments in pharma and agriculture.

These new capabilities are expected to extend the range of Evogene's GeneRator AI solution by supporting products based on changes in genetic elements via genome editing.

Dr. Eyal Emmanuel, Chairman of the CRISPR-IL consortium and CSO of Evogene commented: "We are proud of the consortium's advancement according to plan and the launch of the first version of a genome editing design platform. We are happy to welcome new partners to the consortium that allow the increased application of this technology to existing and new areas such as alternative protein-based on insects. We believe that CRISPR-CAS based genome-editing holds great promise, and that the work of the CRISPR-IL consortium positions both Israel and Evogene at the forefront of applicability of CRISPR technologies."

About the CRISPR-IL consortium:

The CRISPR-IL consortium was established to develop an artificial intelligence-based system, "Go-Genome", providing users genome-editing workflows with improved precision and efficiency. This system is intended to be effective in multi-species, including human, plant, and certain animal DNA applicable to market segments in pharma, agriculture, and aquaculture. For more information see the press release from June 3rd, 2020.

CRISPR-IL participants include leading companies, medical institutions, and academic institutions. In addition to Evogene, participants include: Better Seeds, BTG – Bio-technology General Israel, Colors Farm, FreeZem, Hazera Seeds, NRGene, Pluristem, Rahan Meristem Ltd., TargetGene; medical institutions: Sheba Medical Center, Schneider Children's Medical Center; and academia: Bar-Ilan University, Ben Gurion University of the Negev, Hebrew University of Jerusalem, IDC Herzliya, Tel-Aviv University and the Weizmann Institute of Science.

The CRISPR-IL consortium was approved in June 2020. Its budget for the initial period is approximately ILS 36 million (approximately $10 million), partially funded by a grant from the Israeli Innovation Authority.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN), (TASE: EVGN) is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform to develop human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. For more information, please visit www.evogene.com.

[Porterhouse10]

Looks like a big run up, any chance she cools off to $3.95-$4.10 be nice entry jmo

[Jaydixson1]

Ark has been buying evgn

[midastouch017]

Lavie Bio Provides Product Pipeline Update for 2020

Tue, December 29, 2020, 2:00 PM GMT+2

LAV211 bio-stimulant advancing towards anticipated 2022 commercial launch in spring wheat; Product advancement achieved in multiple programs

REHOVOT, Israel, Dec. 29, 2020 /PRNewswire/ -- Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), has announced an update on certain advancements achieved in its pipeline in 2020, including phase advancement of bio-stimulant LAV211, towards an anticipated commercial launch in 2022.

"Our commitment and main focus at Lavie Bio is to develop novel microbiome based ag-biological products, bio-pesticides & bio-stimulants that address the dire need for new tools to increase agriculture productivity while improving sustainability and food quality. 2020 was a remarkable year in our journey to achieve these targets," stated Mr. Ido Dor, CEO of Lavie Bio.

Bio-stimulants pipeline:

LAV211 Bio-stimulant Targeting Spring Wheat – Initially targeting approximately 25 million acres of spring wheat in North America,[1] LAV211 is Lavie Bio's leading product candidate in this program. According to Lavie Bio's estimates, and assuming current agricultural commodity prices, a viable and effective bio-stimulant could generally be expected to provide farmers with additional value that translates to at least $20, on average, of income per farmed acre.

LAV211 is advancing into the pre-commercial phase,[2] following field trials in target locations, meeting development criteria and outperforming trial controls, which included competitor benchmarks. Additionally, LAV211 received product registration approval this year in North Dakota and Montana, key target markets for growing spring wheat. Additional commercial scale trials are planned for 2021, in preparation for product launch planned for 2022. Lavie Bio intends to evaluate potential expansion of LAV211 to additional crops.

Bio-stimulant for Corn – This program is in the pre-development phase.[2] Following results obtained in recent seasons, a subset of candidates is expected to undergo further optimization and additional trials. In addition, during 2021, potential expansion opportunities of the candidates for additional crops are expected to be evaluated. Part of this program is under Lavie Bio's collaboration with Corteva, Inc. (previously DuPont).[3]

Bio-pesticides pipeline:

LAV311 & LAV312 Targeting Bunch Rot Diseases – Chemical crop protection expenditure for bunch rot diseases is estimated at over $200 million annually.[4] Bio-fungicides LAV311 and LAV312 are designed to integrate into the farmer's existing IPM (Integrated Pest Management) practices. Lavie Bio's initial focus is on grapes and it intends to broaden this solution to other fruit.

As announced last month, LAV311 and LAV312 advanced to "Development Stage 2".[5] This follows successful results in vineyard trials, conducted in target locations in Europe and the U.S. The trials' results showed significantly better efficacy and consistency than existing comparable tested commercial biological benchmarks and were competitive to tested commercial chemical benchmarks. In 2021, Lavie Bio intends to further improve the formulation technology and fermentation protocol of LAV311 and LAV312 and expand these solutions to additional crops. Lavie Bio is targeting a product launch for 2024.

Bio-fungicides Targeting Downy Mildew – Downy mildew is a devastating disease with an urgent need for new solutions. Current chemical crop protection expenditure against downy mildew is estimated at over $350 million annually.[4] Lavie Bio's initial focus is on grapes and it intends to broaden its solution to other fruit and vegetable crops.

During 2020, Lavie Bio tested leading candidates that demonstrated positive preliminary results in field trials. Additional candidates were introduced into the pipeline and underwent lab and greenhouse testing. In 2021, select candidates are expected to be tested in target locations in Europe.

Bio-fungicides Targeting Seedling Diseases – The average annual expenditure for crop protection against seedling diseases is over $500 million,4 with leading commercial chemicals under regulatory pressure and resistance emergence posing a risk. Lavie Bio believes that biological solutions have the potential to play an important role in addressing these challenges. Lavie Bio's initial focus is on corn and it intends to expand its solution to soybean and other crops.

In 2020, Lavie Bio's new candidates were validated in lab and greenhouse trials with positive results. Leading candidates are undergoing further development with field testing planned for target locations during 2021.

Bio-insecticides Targeting Western Corn Root Worm (WCRW) – The annual overall expenditure on protection against WCRW, including genetically modified corn seed traits (biotech traits) and chemical insecticides, exceeds $1.5 billion.[6] Biological insecticides could be integrated into the farmer's existing IPM either with biotech traits or combined with chemical solutions. During 2019-2020, Lavie Bio introduced additional candidates to its pipeline, which were validated in lab, greenhouse and field trials. In 2021, Lavie Bio expects to test leading candidates in multi-location fields in target territories and in parallel further optimize their formulations.

Mr. Ido Dor added: "The sustainable approach of ag-biologicals holds a significant promise for the future of agriculture, and we are excited to be at the forefront of this area. We are confident Lavie Bio has an excellent opportunity, powered by our Biology Driven Design (BDD) platform, to make a real impact for both growers and consumers and look forward to sharing our progress over the coming year, as our vision advances towards commercialization of our initial products."

Mr. Ofer Haviv, Chairman of Lavie Bio and CEO & President of Evogene, stated: "We are pleased with the progress that Lavie Bio achieved in its product pipelines in 2020. The use of Lavie Bio's computational BDD platform, powered by Evogene's 'MicroBoost AI' engine, has led Lavie Bio to reach impressive achievements in multiple product pipelines. I am confident that Lavie Bio is on the right track to becoming a global leading ag-biologicals company, introducing multiple novel products in the coming years."

About the Biology Driven Design (BDD) Platform

The BDD platform facilitates and accelerates the design and development of microbiome-based products through the decoding of complex microbiome/host interactions and the identification of the key genetic elements (functions) governing these interactions. This decoding, which enables amplification of positive or elimination of negative, and/or the retrieval of lost interactions, is powered by big data and artificial intelligence, provides the basis for products design. The enabling technology for the establishment of the BDD platform was the MicroBoost AI engine, a component of Evogene's Computational Predictive Biology (CPB) platform and the Taxonia platform acquired as part of the Taxon Biosciences acquisition.

About Lavie Bio Ltd.:

Lavie Bio, a subsidiary of Evogene Ltd., aims to improve food quality, sustainability and agriculture productivity through the introduction of microbiome based ag-biological products. Lavie Bio utilizes a proprietary computational predictive platform, the BDD platform, harnessing the power of big data and advanced informatics, for the discovery, optimization and development of bio-stimulants and bio-pesticides products. Corteva, Inc. holds approximately 28% in Lavie Bio. For more information, please visit www.lavie-bio.com.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN) (TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ag Ltd. For more information, please visit www.evogene.com.

[midastouch017]

5.37+1.44 (+36.62%)
As of 1:03PM EST. Market open.
Just broke (again) the 52 w/h

[midastouch017]

5.21+1.28 (+32.57%)
As of 12:48PM EST. Market open.

Volume 5,005,609
Avg. Volume 1,135,076

WoW!